hydroxychloroquine has been researched along with piperacillin, tazobactam drug combination in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antunes de Brito, CA; Falcão, MB; Filgueiras Filho, NM; Pamplona de Góes Cavalcanti, L | 1 |
| Fustini, E; Gennarini, S; Mattioli, M | 1 |
2 other study(ies) available for hydroxychloroquine and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychloroquine; Liver; Lung; Pandemics; Piperacillin, Tazobactam Drug Combination; Pneumonia, Viral; Respiration, Artificial; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; Cough; COVID-19; COVID-19 Drug Treatment; Diarrhea; Enoxaparin; Enzyme Inhibitors; Exanthema; Fever; Glucocorticoids; Heart Transplantation; Humans; Hydroxychloroquine; Hypoxia; Immunocompromised Host; Immunosuppressive Agents; Male; Methylprednisolone; Middle Aged; Nausea; Piperacillin, Tazobactam Drug Combination; Pulmonary Disease, Chronic Obstructive; Renal Insufficiency, Chronic; SARS-CoV-2; Tachypnea; Treatment Outcome | 2020 |